483
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA 483, Jul 30, 2012
Record Details
An FDA inspection of Celgene Corporation's Summit, NJ facility revealed two significant issues. The firm failed to thoroughly review unexplained discrepancies, specifically concerning an off-white appearance defect in Azacitidine for Injection lots. Additionally, there was no written program for assessing drug product stability, and numerous Revlimid Capsule stability samples were not properly logged into stability chambers.
View Company Profile
ID · 10c364b5-0a3f-4a9c-9052-a72355ca9483
Other documents for Bristol-Myers Squibb Company
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.